drug adverse effects of calcium channel blockers
Jump to navigation
Jump to search
Adverse effects
- lower extremity edema, pedal edema
- diuretics (including loop diuretics) are ineffective in treating calcium channel blocker (CCB)-induced edema[13]
- CCB-induced edema is due to arteriolar vasodilation rather than excess plasma volume
- ACE inhibitors & ARBs can counteract CCB-induced edema
- CCB-induced arteriolar vasodilation causes edema by increasing capillary pressure
- ACE inhibitors or ARBs can lower that increased capillary pressure by decreasing postcapillary resistance[14]
- bradycardia
- tachycardia
- orthostatic hypotension
- constipation
- GERD via lowering of esophageal sphincter tone
- urinary retention via relaxation of bladder smooth muscle
- eczema, pruritus (especially chronic therapy in elderly)[2][3][9][10]
- generally occurs about 3 months after starting drug[3]
- histopathology may be spongiform[9]
- photosensitivity[3]
- erythema multiforme, exfoliative dermatitis[3] (rare)
- long-term use of calcium channel blocker associated with > 2-fold increased risk of breast cancer in postmenopausal women[7]
- no association with increased risk for breast cancer[8]
- in older adults > 66 years of age, prescription of calcium-channel blocker associated with increase likelihood of later prescription of loop diuretic[11]
- tetrad of hypotension, bradycardia, hyperglycemia, metabolic acidosis
- also see calcium channel blocker
More general terms
References
- ↑ Daubert GP, Emergency Medicine, University of California, Davis
- ↑ Jump up to: 2.0 2.1 Joly P et al, Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: Results from a cases-control study. J Invest Dermatol 2007, 127:2766 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17713574
Stern RS Chronic medication use and inflammatory skin diseases: The power and limitations of the case-control study. J Invest Dermatol 2007, 127:2709 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18007690 - ↑ Jump up to: 3.0 3.1 3.2 3.3 3.4 Prescriber's Letter 15(4): 2008 Calcium Channel Blockers (CCBs) and Eczema Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=240402&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 15, American College of Physicians, Philadelphia 2009
- ↑ The Washington Manual of Medical Therapeutics, 33rd edition Foster C et al (eds) Lippincott, Williams & Wilkins, Philadelphia, 2010, pg 971
- ↑ Summers EM et al. Chronic eczematous eruptions in the aging: Further support of an association with exposure to calcium channel blockers. JAMA Dermatol 2013 May 1 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23636109 <Internet> http://archderm.jamanetwork.com/article.aspx?articleid=1684846
- ↑ Jump up to: 7.0 7.1 Li CI, Daling JR, Tang MT et al Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years. JAMA Intern Med. August 5, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23921840 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=1723871
Coogan PF Calcium-Channel Blockers and Breast Cancer.A Hypothesis Revived. JAMA Intern Med. August 5, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23921818 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=1723870 - ↑ Jump up to: 8.0 8.1 InterMountain Health Care. Study deputes previous claims that calcium channel blocker meds cause breast cancer. http://intermountainhealthcare.org/hospitals/imed/services/heart-institute/about/Pages/news.aspx?NewsID=1867
- ↑ Jump up to: 9.0 9.1 9.2 Summers EM, Bingham CS, Dahle KW, et al. Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers. JAMA Dermatol. 2013;149(7):814-818. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23636109
- ↑ Jump up to: 10.0 10.1 Orme S, da Costa D. Generalised pruritus associated with amlodipine. BMJ. 1997;315(7106):463. PMID: https://www.ncbi.nlm.nih.gov/pubmed/9284667
- ↑ Jump up to: 11.0 11.1 Savage RD, Visentin JD, Bronskill SE et al. Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension. JAMA Intern Med 2020 Feb 24; PMID: https://www.ncbi.nlm.nih.gov/pubmed/32091538 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2761272
- ↑ DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev 2004; 23:223 PMID: https://www.ncbi.nlm.nih.gov/pubmed/15898828
- ↑ Jump up to: 13.0 13.1 Rochon PA et al. Association of a calcium channel blocker and diuretic prescribing cascade with adverse events: A population-based cohort study. J Am Geriatr Soc 2024 Feb; 72:467. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38009803 https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.18683
- ↑ Jump up to: 14.0 14.1 Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker- Associated Peripheral Edema. Am J Med. 2011 Feb;124(2):128-35 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21295192 https://www.amjmed.com/article/S0002-9343(10)00745-X/fulltext